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Abstract
Background: Effective therapeutic management of elderly patients with cancer, on an individual basis, remains a
clinical challenge. Here, we identify novel biomarkers to assess elderly patients (≥70 years of age) with breast
cancer undergoing treatment with or without chemotherapy.
Methods: We performed comprehensive geriatric assessment and measured markers sensitive to alteration in
ageing, including leukocyte telomere length, CMV serostatus, levels of circulating growth factors and cytokines, and
immune profiling of T cell and myeloid populations in blood before and at 3 months and 12 months after initiation
of therapy, using flow cytometry.
Results: We observed changes in immune profiles over time that were specific to patients receiving chemotherapy;
these patients had elevated CD4+ T effector memory re-expressing CD45RA (TEMRA) cells and relatively lower CD8+
central memory cells at 3 months, with normalized levels after 12 months. Patients’ baseline immune profiles correlated
with markers such as telomere length, cytomegalovirus (CMV) serostatus and levels of circulating cytokines. We also
identified correlations between baseline immune profile and geriatric assessment, i.e. more frail patients had higher levels
of granulocytic cells but lower levels of cells with suppressor phenotypes including myeloid-derived suppressor cells and
regulatory T cells, although none of the examined immune populations correlated with chronological age. Importantly,
immune profiles prior to therapy predicted unexpected hospitalizations in patients receiving chemotherapy.
Conclusion: These findings suggest that immune profiling may represent a novel complementary approach to more
accurately assess the global health status of the elderly patient with breast cancer and select the most appropriate
individual treatment option.
Trial registration: ClinicalTrials.gov, NCT00849758. Registered on 20 February 2009.
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Background
Breast cancer is one of the most common cancers in
elderly women, but only recently have steps been taken
to standardize treatments for older patients [1, 2]. The
high variability of individual health status in the elderly
constitutes a major challenge in offering optimal therapy
to this population. A comprehensive geriatric assessment
(GA) allows an evaluation of the general health status of
older patients, and predicts treatment toxicity and out-
come to some extent [3], but it is still an imperfect,
time-consuming tool and there is a lack of consensus on
which specific geriatric scales should be used. Based on
our own findings, biological markers of ageing and
frailty could provide added value to clinical geriatric
evaluation for assessing individual patients’ fitness [4].
Age-associated immune dysfunction or “immunose-
nescence” decreases the ability of older people to mount
immune responses and results in inappropriate and
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prolonged inflammatory reactions, which may contribute
to the development and/or progression of cancer.
Hallmarks of an aged immune system are increased out-
put of myeloid cells from the bone marrow and a con-
comitant decrease in B cells and T cell progenitors.
Predominantly because of thymic involution early in life
and exposure to pathogens throughout life (especially per-
sistent viruses such as cytomegalovirus (CMV)), the older
person’s immune system comprises quantitatively different
cell types relative to younger people, with a predominance
of memory T cells and deficit of naïve cells that have not
yet been exposed to their cognate antigen. Moreover,
immune cells may be functionally compromised in older
people, with some showing signs of cellular senescence
(short telomeres, accumulated DNA damage, and in-
creased expression of cell-type-restricted surface mole-
cules such as CD57 on CD8+ T cells).
Although not specific, the surface marker constellations
measured on the T cell surface by flow cytometry can
provide information about the “age” of that individual’s
immune system [5]. Exposure to chemotherapy may
exacerbate this immune ageing effect in elderly patients
with cancer and render them more susceptible to diseases
associated with dysregulated immunity [6]. Depending on
the kinetics of the response, chemotherapeutic agents may
also influence T cell-mediated anti-cancer responses,
which can be assessed as functional “immune signatures”
[7, 8]. However, the impact of chemotherapy on immuno-
senescence has been poorly investigated. Here, we investi-
gated markers of immunosenescence in an older population
of patients with breast cancer, who were receiving adjuvant
chemotherapy, and compare these changes to patients with
breast cancer who were not receiving chemotherapy, in
order to examine chemotherapy-dependent effects on the
immune system. Additionally, we tested correlation between
these immune changes and clinical frailty defined by
geriatric assessment, and other potential ageing biomarkers
such as telomere length in white blood cells and circu-
lating inflammatory cytokines, and assess the capacity
of immune biomarkers to predict patient outcome
following chemotherapy.
Methods
Patient population
This is a biomarker sub-study from a previously reported
prospective clinical study evaluating the effect of adjuvant
chemotherapy on clinical and biological ageing parameters
in older female patients (≥70 years) with breast cancer [9]
(trial registration number NCT00849758 (www.clinical-
trials.gov)). In brief, this was a prospective, multicenter,
non-interventional study in which patients were recruited
at two academic and two regional hospitals in Belgium be-
tween 2009 and 2012. Eligible patients were women aged
70 years or older with early invasive breast cancer, who
were to receive adjuvant chemotherapy (4 × docetaxel-
cyclophosphamide (TC)) (chemotherapy group (CTG)). It
should be pointed out that TC was combined with trastu-
zumab in human epidermal growth factor receptor 2
(HER2)-positive patients in the CTG. All therapy was ad-
ministered according to established risk factors and inter-
national guidelines [2]. In parallel, a control group
consisted of patients with early breast cancer (≥70 years)
in whom adjuvant chemotherapy was not indicated, and
who were treated with an aromatase inhibitor as the sole
adjuvant systemic therapy (control group (CG)). Written
informed consent was obtained from all patients and the
study was approved by the ethics committees of the par-
ticipating hospitals.
Patients were enrolled after surgery and underwent
blood sampling and full geriatric assessment (GA) and
quality of life (QoL) evaluation at baseline, after
3 months and after 1 year. The first time point for blood
draw was typically between 3 and 6 weeks after surgery,
and always before administration of the first TC cycle in
the CTG. The second time point was on the day of the
fourth and last TC cycle (blood was taken immediately
prior to chemotherapy administration) for patients in
the CTG and approximately 3 months after inclusion for
patients in the CG. The last time point was roughly
1 year after inclusion for both groups, or on the day
before eligible patients received the 18th and last dose of
trastuzumab.
GA was performed on all patients by a trained nurse.
We performed a G8 screening test in all patients at base-
line, and a full GA in all patients at the three time points
as previously described [10]. In brief, the full GA consisted
of social data, functional status assessed by Katz’s activities
of daily living (ADL) and by Lawton’s instrumental activ-
ities of daily living (IADL) scales, fall history, self-
perceived fatigue assessed by the mobility–tiredness test
(MOB-T), cognitive status assessed by the mini mental
state examination (MMSE), mood assessed by the 15-item
geriatric depression scale (GDS-15), nutritional status
assessed by the mini nutritional assessment-short form
(MNA-SF) and comorbidity assessed by the Charlson co-
morbidity index (CCI).
Classical oncological parameters such as Eastern Co-
operative Oncology Group-performance status (ECOG-
PS) [10], tumor characteristics (tumor molecular subtype
according to the St. Gallen criteria, and tumor, node and
metastasis (TNM) staging) and treatment details and
toxicity were also recorded. Pain was evaluated in every
patient using a visual analog scale (VAS). Polypharmacy
was assessed by the number of different registered drugs
(http://www.bcfi.be/nl/start) the patient was using during the
week preceding study inclusion. Quality of life was assessed
with the European Organization for Research and Treatment
for Cancer quality of life questionnaire (EORTC QLQ-C30)
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at the three time points. Combined GA results were
categorized according to the Leuven oncology frailty
score (LOFS), which summarizes GA results in a sin-
gle score, ranging from 10 (very fit) to 0 (very frail)
[9]. Overall clinical health was similar in the CG and
CTG groups, although the controls had slightly worse
clinical health profiles. Additional file 1 provides a
detailed description of these cohorts.
Immunophenotyping of blood leukocyte populations
The initial biomarker study [9] comprised 57 patients in
the CTG and 52 controls. Frozen blood samples of suffi-
cient quality for immune phenotyping were available at
the three defined time points in 28 patients in each
group. Collected whole blood was stored at −80 °C as
previously described [11]. Briefly, dimethyl sulfoxide
(DMSO) was added to each tube in a drop-wise manner
to a final concentration of 10%; the solution was mixed
well by gentle agitation and transferred to a plastic
15 ml tube. Samples were immediately placed at −80 °C
before being shipped to Tübingen for storage in liquid
nitrogen until use.
To perform immunophenotyping, frozen samples were
thawed in a 37 °C water bath and immediately washed
with a 24-fold excess of cold PBS supplemented with
2.0 mM EDTA (Serva, Heidelberg, Germany) and 2%
fetal bovine serum (FBS). The diluted blood was gently
inverted by hand three to four times to mix before
undergoing centrifugation (×300 g at room temperature
for 5 minutes). The supernatant was aspirated by pipette
and samples were then treated with lysis buffer (BD Bio-
sciences, Heidelberg, Germany) for 15 minutes and
washed with phosphate buffered saline, 2% FBS, 2 mM
EDTA and 0.01% azide (PFEA).
Before staining for different immune populations, Fc
receptors were blocked with Gamunex (Bayer, Leverkusen,
Germany) and dead cells labelled with the DNA-binding
dye Ethidium Monoazide Bromide (Biotium, Hayward,
USA) at 4 °C under bright light for 20 minutes in a single
step. Then, 1.5 ml of diluted blood was used for each
panel of fluorescently-labeled antibodies, combining
markers of different cell types as follows: for T-cells: CD3-
Alexa Fluor700, CD4-PerCp, CD8-APC-H7, CCR7-PO,
CD27-APC, CD28-PE, CD45RA-V450, CD57-FITC and
CD95PE-Cy7; for regulatory T cells (Tregs): surface
CD4-PerCp, CD8-APC-H7, CD45RA-BV421, CD25-PE
followed by intracellular staining of CD3-PO, FOXP3-
Alexa-647 and Helios-FITC; for myeloid-derived
suppressor cells (MDSCs): lineage cocktail (Lin) markers
(CD3, CD19, CD56)-BV-605 along with the MDSC
markers CD14-BV711, CD15-FITC, CD11b-APC-Cy7,
CD33-Alexa-Fluor700, CD45-V500, CD124-PE and HLA-
DR-PerCp-Cy5.5. Additional files 2, 3 and 4 show the
gating strategy used and Additional file 5 displays a full list
of leukocyte populations examined along with a non-
technical explanation of the major marker proteins used.
Measurement of CMV serostatus, plasma cytokines and
chemokines and leukocyte telomere lengths
Blood was collected at 3 time points in 4 ml EDTA K2E
tubes for plasma isolation and leukocyte DNA extrac-
tion. Blood tubes were centrifuged within 1 hour at ×
1300 g at 4 °C for 10 minutes, and plasma was aliquoted
for storage at –80 °C. The buffy coat of the plasma tube
was kept at –20 °C for a maximum of 4 months prior to
DNA extraction for telomere length assessment.
The following biomarkers were assessed as previously
described [9]: mean leukocyte telomere length (TL), CMV
serostatus, circulating inflammatory cytokines and growth
factors IL-6, IL-10, insulin-like growth factor (IGF)-1,
TNF-alpha, monocyte chemoattractant protein (MCP)-1
and regulated on activation, normal T cell expressed and
secreted (RANTES).
Endpoints
The primary aim of this biomarker study was to investi-
gate how immune cell biomarkers (T cells, Tregs and
myeloid-derived suppressor cells (MDSCs)) evolve over
time in elderly patients with breast cancer on chemother-
apy and whether this is different from control patients.
Second, in all patients we assessed correlation between
immune biomarkers (T cells, Tregs, MDSCs) with CMV
status at inclusion (because whether or not the patient is
infected with CMV has a major impact on the distribution
of immune cells in the blood), age at diagnosis, clinical
ageing status (G8 screening tool and a summarized scale
of a full GA, the LOFS), telomere length and circulating
inflammatory and anti-inflammatory cytokines (IL-6, IL-
10, IGF-1, TNF, MCP-1 and RANTES). Third, in the
chemotherapy group we also assessed whether immune
biomarkers measured at inclusion predict decline in func-
tionality (decline by 1 point or more in IADL at 1 year)
and quality of life (10 points or more decrease at 1 year)
in elderly patients receiving chemotherapy. Finally, we also
investigated whether immune biomarkers measured at
inclusion predict chemotherapy-induced grade II-III-IV
toxicity and/or unexpected hospitalizations during the 3-
month treatment period.
Statistics
Continuous immune biomarkers were modeled by linear
models and CMV by a logistic regression model, with
time, study arm and their interaction as explanatory var-
iables. An unstructured residual covariance matrix was
modeled to account for clustering by repeated measures.
Outcomes were transformed where needed, to improve
the symmetry of distribution of the residuals. Spearman
correlation was tested to study the association between
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immune biomarkers and continuous or ordinal variables.
The Kruskal-Wallis test was used to compare biomarkers
among more than two groups. The Mann-Whitney U test
was used to compare two groups. Fisher’s exact test was
used to study the association between CMV and categor-
ical variables. All tests were two-sided with a significance
threshold of 5%. This was a hypothesis-generating study
that did not necessitate correction for multiple testing. As
such, all p values are exploratory and require validation in
an independent cohort.
Results
Impact of chemotherapy on the immune profile of elderly
patients with breast cancer
To investigate therapy-dependent effects on the immune
system, we monitored the immune profiles of elderly pa-
tients with breast cancer in the chemotherapy group
(CTG) and the control group (CG) (28 patients in each
group). Peripheral immune profiles were measured prior
to receiving treatment and 3 months and 12 months
after starting therapy. Patients receiving chemotherapy
had increased frequencies of total CD8+ T cells (mostly
cytotoxic T cells) after 3 months, resulting in a decreased
ratio of CD4:CD8 (Table 1). In the analysis of suppressor
leukocytes, two major populations of MDSCs (CD14 +
HLA-DR– and CD14 + CD124+), but not Tregs, were
increased at 3 months. In contrast to these observations
at 3 months, naïve CD8+ T cells were elevated in
patients in the CTG group after 12 months, while the
two MDSC populations that had increased by 3 months
remained elevated at 12 months. Furthermore, the ele-
vated CD4:8 ratio observed at 3 months was normalized
after 12 months. Table 1 provides a full list of leukocyte
populations that were altered in patients receiving
chemotherapy. Graphical results for these populations
can be found in Additional file 6. Background informa-
tion on these leukocyte populations can be found in
Additional file 5.
We tested whether the evolution over time was differ-
ent between the groups (Table 1, “Time by group inter-
action” shows the comparison between the CTG and
CG groups), and identified chemotherapy-specific effects
on the immune system. There were significant differ-
ences between the CTG and the CG groups in the ratio
of CD4:CD8 T cells, which was slightly lower at 3 months
in CTG patients before approaching normalization again
Table 1 Changes in immune profile in patients undergoing chemotherapy
Inclusion vs 3 months (CTG) Inclusion vs 1 year (CTG) Time by group interaction
Mean difference (95% CI) p Value Mean difference (95% CI) p Value p Value
CD4 + CD27+ –1.64 (–7.27; 3.98) 0.561 8.34 (1.53; 15.15) 0.017 0.317
CD4 + CD28+ –2.11 (–6.33; 2.11) 0.321 5.78 (0.71; 10.85) 0.026 0.018
CD4 + CD27 + CD28+ –0.55 (–5.92; 4.81) 0.836 8.72 (2.22; 15.22) 0.009 0.328
CD4+/central memory 2.65 (–0.57; 5.88) 0.105 6.44 (3.4; 9.48) <0.001 0.114
CD4 + CD27– 0.34 (0.11; 0.57) 0.005 –0.26 (–0.47; –0.04) 0.020 <0.001
CD4+/TEMRA 0.23 (0.03; 0.43) 0.028 –0.09 (–0.28; 0.1) 0.343 0.008
CD8+ 7.69 (2.62; 12.75) 0.004 4.04 (–0.72; 8.8) 0.095 0.116
CD8 + CD27+ –4.77 (–8.8; –0.74) 0.021 2.10 (–1.85; 6.06) 0.292 0.008
CD8 + CD28+ –5.53 (–11.3; 0.24) 0.060 3.99 (–2.84; 10.83) 0.246 0.011
CD8 + CD27 + CD28+ –4.31 (–8.15; –0.46) 0.029 3.91 (0.62; 7.2) 0.021 0.004
CD8 + CD27-CD28– 6.35 (1.78; 10.92) 0.007 –4.42 (–9.18; 0.35) 0.068 <0.001
CD8+/central memory –0.15 (–0.35; 0.05) 0.130 0.27 (0.07; 0.48) 0.009 0.01
CD8+/naive –0.16 (–0.40; 0.09) 0.204 0.29 (0.06; 0.52) 0.014 0.151
CD4/CD8 ratio –0.19 (–0.32; –0.07) 0.003 0.02 (–011; 0.15) 0.757 0.022
CD4 + CD25hi FOXP3+ –0.02 (–0.19; 0.15) 0.857 0.17 (0.02; 0.33) 0.028 0.185
CD4 + Helios+ –0.07 (–1.14; 1.01) 0.903 0.99 (0.18; 1.8) 0.017 0.511
Lin-CD14+ 0.20 (–0.07; 0.47) 0.151 0.58 (0.33; 0.83) <0.001 0.021
CD14 + HLA-DR– 0.13 (0.01; 0.26) 0.039 0.21 (0.08; 0.34) 0.002 0.591
CD14 + CD124+ 0.06 (0.01; 0.11) 0.014 0.07 (0.02; 0.12) 0.009 0.092
CD15+ 0.44 (0.04; 0.83) 0.031 –0.57 (–1.15; 0.01) 0.054 0.018
Mean differences are shown in measurements made at inclusion and at 3 months (n = 28) and at inclusion and at 1 year (n = 28) in the chemotherapy group
(CTG), and these were compared to patients who did not receive chemotherapy (Time by group interaction) (n = 28). Only cell populations with statistically
significant relationships are shown. Naïve CD45RA + CCR7 + CD27 + CD28+, Central memory CD45RA-CCR7 + CD27 + CD28+, TEMRA CD45RA + CCR7-CD27-CD28–.
P values in bold are statistically significant
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after 1 year (Fig. 1a). This is in agreement with the ob-
served increase of CD8+ cells at 3 months in the CTG but
not the CG, and indicates a difference in the balance between
CD4+ and CD8+ T cells. CD4+ cells are mostly “helper” cells
but also include populations of Treg suppressor cells, while
CD8+ Tcells are mostly cytotoxic cells.
The evolution of CD8 + CD27-CD28– cells, CD4+
TEMRA memory cells and CD15+ granulocytic cells
over time was also different in CTG and CT patients; it
had increased by 3 months in the CTG, but not in the
CG, before normalizing again at 1 year (Fig. 1b-d). There
were changes in CD8+ central memory cells and CD8+
CD27+ CD28+ double-positive T cells in the opposite
direction (i.e. relatively lower levels at 3 months before
normalization at 1 year) in CTG patients compared with
CG patients (Fig. 1e, f ). A number of other cell popula-
tions also differed over time in CTG patients compared
to CG patients (Table 1 provides an overview, and the
full set of graphical results are in Additional file 6).
Background information on these leukocyte populations
is in Additional file 5.
CMV status, plasma cytokines, and telomere length are
associated with immune profiles in elderly breast patients
with cancer
We tested for associations between patient immune pro-
files and markers of patient health status including
leukocyte telomere length, CMV serostatus, circulating
cytokines and chemokines and the growth factor IGF-1
in the entire patient cohort at baseline (i.e. the CTG and
CG combined, prior to any systemic therapy). A number
of leukocyte populations were related to plasma IL-6,
IL-10, IGF-1, TNFα, MCP-1 and RANTES (Table 2).
High IL-6 in blood has been linked to poor health status
in numerous studies, so it was interesting that we ob-
served inverse associations between plasma IL-6 and one
MDSC population and putatively senescent CD4 + CD57
+ T cells. There was also correlation between T cells and
a number of other parameters. For instance, frequencies
of CD8+ effector memory cells were inversely associated
with telomere length, while there was positive correl-
ation with CD4+ expressing Helios, a Treg population
that remains poorly defined [12]. As expected based on
numerous studies, CMV seropositivity was associated
with lower frequencies of naïve and central memory T
cells and higher frequencies of late-stage differentiated
TEMRA and effector memory CD4+ T cells. The same
was true in the CD8 compartment except in the case of
effector memory cells, for which there was a trend
towards higher frequency in CMV+ patients. Table 2
provides a comprehensive list of immune profiles that
were significantly correlated with biomarkers of ageing.
Patient immune profile is correlated with clinical frailty as
measured by geriatric evaluation
In view of the correlation between immune profiles and
health status biomarkers measured prior to therapy in
these older patients with breast cancer, we also investi-
gated whether the pre-treatment immune profile was in-
fluenced by age-related parameters (chronological age or
clinical frailty) in the entire patient cohort. Within this
elderly cohort, there was no correlation between any of
the immune cell populations and chronological age by
itself. On the contrary, when analyzing clinical frailty,
Fig. 1 Estimated mean immune biomarker levels (with 95% confidence intervals) in patients undergoing chemotherapy (green lines) or not
having chemotherapy (blue lines) at baseline, 3 months and 12 months after starting therapy. Relative to patients not receiving chemotherapy
(control group (CG)), those receiving chemotherapy (chemotherapy group (CTG)) had a lower ratio of CD4:CD8 T cells at 3 months before partial
normalization (a), while there were relative increases in CTG patients at 3 months followed by normalization at 12 months in CD8 + CD27-CD28–
(b) CD4+ T effector memory re-expressing CD45RA (TEMRA) memory cells (c) and CD15+ granulocytic cells (d). There were relative decreases in
CD8+ central memory cells (e) and CD8+ CD27+ CD28+ T cells (f) in the CTG at 3 months before normalization. Chemo chemotherapy group
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Table 2 Associations between patient immune profile and biomarkers of ageing in the whole population (the CTG and CG) prior to
receiving any systemic therapy
Feature Phenotype p Value r Value Number
Telomere length CD8 + effector memory 0.003 r = –0.482 n = 36
Telomere length CD4 + Helios+ 0.031 r = 0.361 n = 36
IL-6 CD4 + CD57+ 0.025 r = –0.316 n = 50
IL-6 CD3 + CD4+ 0.034 r = 0.298 n = 51
IL-6 CD8 + Helios+ 0.014 r = 0.343 n = 51
IL-6 Lin-CD14-HLA-DR- 0.014 r = –0.332 n = 54
IL-10 CD8+/TEMRA 0.030 r = 0.307 n = 50
IGF-1 CD4 + CD57+ 0.035 r = 0.299 n = 50
IGF-1 CD4 + CD25hi FOXP3+ 0.044 r = 0.283 n = 51
TNF CD4 + CD25hi FOXP3+ 0.019 r = –0.326 n = 51
TNF CD4 + FOXP3+ 0.045 r = –0.282 n = 51
TNF CD8 + Helios+ 0.025 r = 0.315 n = 51
TNF CD14 + CD124+ 0.003 r = 0.392 n = 54
TNF CD15+ 0.020 r = −0.317 n = 54
TNF Lin- 0.009 r = 0.353 n = 54
TNF Lin-CD14- 0.029 r = 0.297 n = 54
MCP-1 Lin-CD14+ 0.018 r = 0.320 n = 54
RANTES CD4+ 0.017 r = –0.337 n = 50
RANTES CD8+/TEMRA 0.012 r = −0.352 n = 50
RANTES CD3 + CD4+ 0.012 r = −0.350 n = 51
RANTES CD8 + FOXP3++ 0.001 r = 0.434 n = 51
RANTES CD14-CD15 + CD124+ 0.006 r = 0.370 n = 54
RANTES Lin-CD14-HLA-DR- 0.009 r = 0.354 n = 54
CMV CD4 + CD27+ 0.031↓ n = 47
CMV CD4 + CD27+ CD28+ 0.044↓ n = 47
CMV CD4+/Central memory 0.037↓ n = 47
CMV CD4 + CD27- CD28- <0.001↑ n = 47
CMV CD4+/TEMRA 0.013↑ n = 47
CMV CD4+/Effector memory <0.001↑ n = 47
CMV CD4 + CD28+ <0.001↑ n = 47
CMV CD8+ 0.020↑ n = 47
CMV CD8 + CD27 0.021↓ n = 47
CMV CD8 + CD27 + CD28+ 0.008↓ n = 47
CMV CD8+/Central memory 0.033↓ n = 47
CMV CD8 + CD27- CD28- <0.001↑ n = 47
CMV CD8+/TEMRA <0.001↑ n = 47
CMV CD8 + CD28+ 0.007↓ n = 47
CMV CD4CD8 ratio 0.004↓ n = 47
CMV CD8 + FOXP3++ 0.039↓ n = 48
Negative r values indicate inverse association and positive r values indicate positive correlation between the patient feature (“Feature”) and the leukocyte
population (“Phenotype”); ↓ indicates that cytomegalovirus (CMV) positive status is associated with lower values of the particular cell population and ↑ indicates
higher values. CTG chemotherapy group, CG control group, IGF insulin-like growth factor, MCP monocyte chemattractant protein, RANTES regulated on activation,
normal T cell expressed and secreted
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patients with an inferior health status according to the
LOFS had higher frequencies of granulocytic cells (these
cells assist in the innate immune defense against patho-
gens and play a role in inflammation), but lower levels
of granulocytic MDSCs and Tregs, both of which can
suppress the immune system. Along these lines, patients
with lower G8 scores also had lower levels of granulo-
cytic MDSCs and Tregs (Table 3). Aside from these as-
sociations, we did not find any further relationships
between clinical ageing and patients’ immune profiles.
Predictive value of immune profiles in patients receiving
chemotherapy
Because we observed that chemotherapy induced changes
in patient immune profiles and that clinical and biological
health biomarkers were also related to immune profiles, we
investigated whether patient immune profiles measured
prior to chemotherapy administration predict decline in
functionality, decline in quality of life, chemotherapy-
related toxicity or unexpected hospitalizations during the 3-
month treatment period. These analyses revealed that
patients experiencing unexpected hospitalizations had
lower levels of putatively suppressive granulocytic MDSCs
(CD14–/CD15+/CD124+) (p = 0.037) but higher levels of
other granulocytic cells (CD15+) (p = 0.049) (n = 26 for
both). Aside from this, the immune profiles of chemother-
apy patients were not associated with decline in func-
tionality, decline in quality of life or chemotherapy-related
toxicity.
Discussion
The study of biomarkers in the elderly [9] was designed
with the goal of identifying biomarkers that can accur-
ately assess the health status of older patients with
breast cancer and of investigating the impact of chemo-
therapy on these markers of biological and clinical age-
ing. For the first time, the present study combines not
only geriatric assessment (GA), but also measures of
blood-based biomarkers including leukocyte telomere
length, plasma cytokines and growth factors [9], circulat-
ing microRNAs (manuscript submitted) and immune
parameters such as CMV serostatus and circulating
immune cell populations. A large-scale analysis of these
multiple factors was performed in patients with breast
cancer receiving chemotherapy and compared to pa-
tients receiving hormone treatment only.
The present report focuses on the immune bio-
markers; it describes correlation between baseline cellu-
lar immune profiles and potential health indicators such
as telomere length, CMV status and plasma cytokines
and with the patients’ clinical frailty status as measured
by GA. Immune profiles of patients receiving chemo-
therapy were additionally tested for their ability to pre-
dict decline in functionality, decline in quality of life,
chemotherapy-related toxicity or unexpected hospitaliza-
tions. It was hypothesized that chemotherapy may have
a significant short-term and/or longer-term effect on the
immune system. Therefore, we assessed immune profiles
before treatment and at 3 months and 12 months after
the start of therapy, and compared the time-dependent
evolution of diverse immune cell populations in patients
treated with chemotherapy compared to patients who
did not receive chemotherapy.
The potential limitations of this study must be ac-
knowledged in that this study was exploratory, no power
calculations were performed for the analyses reported
and a large number of statistical tests were performed
without correction for multiple testing. Therefore, these
results require validation in an independent cohort.
Nonetheless, the results of this study do support the
hypothesis that there are therapy-dependent effects on
the immune system.
Patients in the control group (CG) underwent surgery
before inclusion in the study, which after inclusion was
Table 3 Patient immune profiles correlating with clinical frailty in the whole population (the CTG and CG) prior to receiving
systemic therapy at baseline
Geriatric measure Phenotype p Value, r value, number
LOFS CD4+/CD57+ 0.0178, r = 0.341, n = 48
LOFS CD8+/CD27 0.0367, r = 0.302, n = 48
LOFS CD4+/CD25hi FOXP3+ 0.0407, r = 0.291, n = 50
LOFS CD4+/FOXP3+ 0.0002, r = 0.510, n = 50
LOFS CD14-negative/CD15+/CD124+ 0.0292, r = 0.303, n = 52
LOFS CD14-negative/HLA-DR-negative/CD11b+ 0.0195, r = 0.323, n = 52
LOFS CD15+ 0.0246, r = -0.311, n = 52
G8 CD4+/FOXP3+ 0.0147, r = 0.340, n = 51
G8 CD14-ve/HLA-DR-negative/CD11b+ 0.0403, r = 0.280, n = 54
Negative r values indicate inverse association and positive r values show positive correlation between patient geriatric status (“Geriatric measure”) and the
indicated leukocyte population (“Phenotype”). Lower G8 and Leuven oncology frailty score (LOFS) values designate more frail patients and high values indicate
fitter patients. CTG chemotherapy group, CG control group
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followed by anti-hormone therapy, and radiotherapy in
most cases. In the chemotherapy group (CTG), the major-
ity of patients also received radiotherapy and anti-hormone
therapy, but all patients additionally received four cycles of
docetaxel-cyclophosphamide. At 3 months and at 1 year
after the start of systemic therapy, there were changes in
the immune profiles of patients receiving chemotherapy.
We observed elevated levels of total CD8+ T cells at
3 months and increased levels of naïve CD8+ T cells at
12 months after the start of chemotherapy, suggesting im-
mune stimulation in chemotherapy-treated patients both
immediately after the completion of chemotherapy and also
in the longer term after the cessation of chemotherapy.
CD8+ T cells are primarily cytotoxic cells that provide im-
munological protection against viral and other infections,
thereby revealing a potential mechanism of chemotherapy-
induced immunomodulation. Naïve CD8+ T cells represent
a primary pathway by which the adaptive immune system
provides immunological protection against novel antigens.
An increase in these cells may result in an enhanced
capacity of these patients treated with chemotherapy to
respond to novel tumor antigens; for example, during
additional rounds of chemotherapy in patients who relapse,
and together with chemotherapy-induced immunogenic cell
death, may represent an additional immunological thera-
peutic mechanism of chemotherapy [13]. However, these
apparent immune stimulatory effects may be balanced out
by elevations in populations of suppressive cells; two popula-
tions of MDSCs were also increased after 3 months and
12 months in patients receiving chemotherapy. This suggests
that in this clinical setting, MDSC-targeted therapies may re-
sult in improved patient status. This observation is also in
contrast to the emerging view that at least some types of
chemotherapy in certain cancers may act to selectively de-
press MDSC function and/or viability, as does doxorubicin
in breast cancer [14], and hence contribute positively to the
beneficial effects of such treatment [15]. In all likelihood, the
end effect of these complex interactions will be highly
context-dependent [16]. For example, hormone therapy has
the potential to influence aspects of the immune system
[17], which may relate to our observations here of therapy-
dependent effects on the immune system; patients in the CG
received hormone therapy as the sole form of systemic treat-
ment, whereas the majority of patients in the CTG group re-
ceived hormone therapy after chemotherapy.
The present study identified a large number of correla-
tions between patient immune profile and biomarkers of
patient biological age and health status, including CMV ser-
ostatus, leukocyte telomere length and circulating cytokines
or growth factors. In accordance with numerous studies
(reviewed in [18]), we observed lower frequencies of naïve
and central memory T cells and higher frequencies of late-
stage differentiated TEMRA and effector memory T cells in
CMV-positive patients, in line with the notion that CMV
infection contributes to immune exhaustion, particularly in
elderly individuals. We also observed inverse correlation
between IL-6 and the CD14-HLA-DR– MDSC population,
but there was no correlation between IL-6 and other
MDSC phenotypes. This suggests that the purported role
of IL-6 in expanding suppressive myeloid cells [19] is not
reflected in human samples analyzed directly ex vivo. Sam-
ples of this type are more likely to be indicative of human
biology, as compared with prior studies, which have investi-
gated the role of IL-6 in expanding MDSCs using animal
models or in vitro cultures of samples of human peripheral
blood mononuclear cells (PBMCs). IL-6 has been reported
to be associated with poor health status in a number of pre-
vious studies (reviewed in [20]). The concomitant alter-
ations in IL-6 and blood leukocytes suggest pathways
through which IL-6 may be related to inferior health status.
The clinical age of these elderly patients with breast can-
cer, as measured with the GA scores LOFS and G8, was re-
lated to certain leukocyte populations in blood. The
observation that patients with an inferior health status
according to the LOFS had higher frequencies of granulo-
cytic cells but lower levels of putatively suppressive gran-
ulocytic MDSCs and Tregs may identify patients who have
an ongoing infection or who have high levels of inflamma-
tion mediated by granulocytic cells that is not dampened by
MDSCs or Tregs, as would usually occur. Moreover, the
combination of high levels of granulocytic cells and low
levels of MDSCs measured at baseline was also related to
the prediction of health issues in patients receiving chemo-
therapy. The finding that patients with unexpected hospi-
talizations had lower levels of putatively suppressive
granulocytic MDSCs but higher levels of other granulocytic
cells is intriguing, and may reflect the result of a latent in-
fection or may be related to high levels of inflammation
that have not been suppressed by this MDSC population.
Conclusion
To the best of our knowledge, this is the first study to
investigate the effect of chemotherapy on the immune sys-
tem in elderly patients with breast cancer using ex vivo ana-
lyses, and also the first to assess the association between
clinical frailty, biomarkers of ageing and immune profiles in
this context. We report that elderly breast patients with
cancer undergoing chemotherapy have alterations in their
immune profiles over time. Furthermore, there is correl-
ation between specific circulating leukocyte populations
measured prior to therapy and biomarkers of ageing,
including telomere length and blood cytokines, and clinical
frailty scored by the LOFS and G8. The immune
biomarkers identified in this study may therefore provide a
novel tool for the assessment of health status in elderly pa-
tients with breast cancer, which may be further developed
in the future to better guide the therapeutic management
of patients with breast cancer on an individual basis.
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